or R-DHAP followed by BEAM plus autologous stem cell transplantation diffuse large B-cell lymphoma is not salvaged by classical R-ICE + MYC

[1]  A. Rosenwald,et al.  The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Schmitz,et al.  Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Sonali M. Smith,et al.  The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. , 2010, Blood cells, molecules & diseases.

[4]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Copie-Bergman,et al.  Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Natkunam,et al.  Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France , 2009, Journal of hematopathology.

[7]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[8]  A. Banham,et al.  Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP , 2009, Modern Pathology.

[9]  L. Mazzucchelli,et al.  BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. , 2009, Human pathology.

[10]  I. Miura,et al.  Clinical significance of 8q24/c‐MYC translocation in diffuse large B‐cell lymphoma , 2009, Cancer science.

[11]  A. Rosenwald,et al.  Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.

[12]  P. Moreau,et al.  The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement , 2007, Haematologica.

[13]  C J L M Meijer,et al.  Immunohistochemical profiling based on Bcl‐2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma , 2006, The Journal of pathology.

[14]  E. Haralambieva,et al.  Detection of three common translocation breakpoints in non‐Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin‐embedded tissue sections , 2002, The Journal of pathology.

[15]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  L. Medeiros,et al.  Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis , 2006, Modern Pathology.

[18]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.